logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8765748 B1

PDFFull Text
Date of Patent:
Jul. 01, 2014

Filed:

Dec. 19, 2008

Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer

Applicants:

Heinz W. Pauls, Oakville, CA;

Bryan T. Forrest, Toronto, CA;

Radoslaw Laufer, Oakville, CA;

Miklos Feher, Toronto, CA;

Peter Brent Sampson, Oakville, CA;

Guohua Pan, Oakville, CA;

Sze-wan LI, Toronto, CA;

Yong Liu, Toronto, CA;

Inventors:

Heinz W. Pauls, Oakville, CA;

Bryan T. Forrest, Toronto, CA;

Radoslaw Laufer, Oakville, CA;

Miklos Feher, Toronto, CA;

Peter Brent Sampson, Oakville, CA;

Guohua Pan, Oakville, CA;

Sze-Wan Li, Toronto, CA;

Yong Liu, Toronto, CA;

Assignee:

University Health Network, Toronto, CA;

Attorneys:

McCarter & English, LLP

Steven G. Davis

Wei Song

Primary Examiner:

Sun Jae Yoo

Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); A61K 31/416 (2006.01); A61K 31/4192 (2006.01); A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/437 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

Find Patent Forward Citations

Loading…